Supernus Pharmaceuticals agreed to acquire Sage Therapeutics at an initial valuation of approximately $561 million, with additional contingent payments potentially increasing the deal value to $795 million. The acquisition adds Sage's FDA-approved oral postpartum depression drug Zurzuvae to Supernus' CNS portfolio, complementing its existing treatments for ADHD and Parkinson’s disease. Despite Sage’s recent setbacks, including a major staff reduction and pipeline challenges, Supernus anticipates strong growth potential with Zurzuvae. The deal is expected to close in the third quarter of 2025 and is seen by some analysts as a pragmatic resolution for Sage.